Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–6 of 6 results
Advanced filters: Author: Fatima Karzai Clear advanced filters

  • Despite improving therapeutic options, the prognosis for patients with metastatic castration-resistance prostate cancer (mCRPC) remains poor. Here, the authors identify MCL1 copy number alterations as a prognostic and predictive biomarker, demonstrating its therapeutic potential as a drug target, either alone or in combination, in patients with mCRPC.

    • Juan M. Jiménez-Vacas
    • Daniel Westaby
    • Adam Sharp
    ResearchOpen Access
    Nature Communications
    Volume: 16, P: 1-22

  • Prostate-specific membrane antigen (PSMA) as a theranostic agent is driving changes in prostate cancer including both clinical development of new drugs and clinical care. The sensitivity of PSMA imaging has created impatience in industry and the clinic alike to replace traditional computed tomography and bone scan in clinical practice and drug development. However, the success of PSMA as a therapeutic target might limit the ability of PSMA imaging to adequately define prostate cancer in a therapeutic landscape where highly effective PSMA-based therapies are used early in the disease course.

    • Melissa L. Abel
    • Adam Sharp
    • Ravi A. Madan
    Comments & Opinion
    Nature Reviews Urology
    P: 1-3

  • Understanding of metastatic prostate cancer is mainly defined by macroscopic findings, but prostate-specific membrane antigen (PSMA) PET has increased sensitivity. PSMA+ serosal-based findings on the surface of the liver and other organs might not have the same implications when seen on PSMA PET versus conventional imaging. Awareness of this phenomenon is important in assessing whether treatment escalation is truly required.

    • Melissa L. Abel
    • Esther Mena
    • Ravi A. Madan
    Comments & Opinion
    Nature Reviews Urology
    P: 1-2

  • Prostate cancer is often a multifocal disease but how best to manage this clinically remains unclear. Here, the authors report a single case study of a patient with two genetically diverse tumours which showed differential response to therapy.

    • Scott Wilkinson
    • Stephanie A. Harmon
    • Adam G. Sowalsky
    ResearchOpen Access
    Nature Communications
    Volume: 11, P: 1-8

  • Beltran and colleagues discuss the challenges in treating metastatic prostate cancer and strategies to accelerate precision oncology and improve therapy and clinical decisions in this setting.

    • Joaquin Mateo
    • Rana McKay
    • Himisha Beltran
    Reviews
    Nature Cancer
    Volume: 1, P: 1041-1053